GBP2 facilitates the progression of glioma via regulation of KIF22/EGFR signaling

Ren, Yeqing; Yang, Biao; Guo, Geng; Zhang, Jianping; Sun, Yanqi; Dong, Li; Guo, Shuqin; Wu, Yongqiang; Wang, Xiaogang; Wang, Shule; Zhang, Wenju; Guo, Xiaolong; Li, Xuepeng; Ren, Li; He, Jianhang; Zhou, Zihan

doi:10.1038/s41420-022-01018-0

Cited by 17 publications

(11 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is despite the fact that GBP-1 can inhibit tumor angiogenesis, inhibit breast cancer proliferation, and directly inhibit actin polymerization [ 9 , 10 , 30 , 34 ]. GBP-2 also promotes a better prognosis in breast and colon cancer [ 23 , 24 , 81 ] ( Table 6 ), but promotes glioblastoma progression [ 43 , 82 ].…”

Section: Discussionmentioning

confidence: 99%

Unraveling the Role of Guanylate-Binding Proteins (GBPs) in Breast Cancer: A Comprehensive Literature Review and New Data on Prognosis in Breast Cancer Subtypes

Hunt

Kopacz

Vestal

2022

Cancers

View full text Add to dashboard Cite

At least one member of the Guanylate-Binding Protein (GBP) family of large interferon-induced GTPases has been classified as both a marker of good prognosis and as a potential drug target to treat breast cancers. However, the activity of individual GBPs appears to not just be tumor cell type–specific but dependent on the growth factor and/or cytokine environment in which the tumor cells reside. To clarify what we do and do not know about GBPs in breast cancer, the current literature on GBP-1, GBP-2, and GBP-5 in breast cancer has been assembled. In addition, we have analyzed the role of each of these GBPs in predicting recurrence-free survival (RFS), overall survival (OS), and distance metastasis-free survival (DMFS) as single gene products in different subtypes of breast cancers. When a large cohort of breast cancers of all types and stages were examined, GBP-1 correlated with poor RFS. However, it was the only GBP to do so. When smaller cohorts of breast cancer subtypes grouped into ER+, ER+/Her2-, and HER2+ tumors were analyzed, none of the GBPs influenced RFS, OS, or DMSF as single agents. The exception is GBP-5, which correlated with improved RFS in Her2+ breast cancers. All three GBPs individually predicted improved RFS, OS, and DMSF in ER- breast cancers, regardless of the PR or HER2 status, and TNBCs.

show abstract

Section: Discussionmentioning

confidence: 99%

Unraveling the Role of Guanylate-Binding Proteins (GBPs) in Breast Cancer: A Comprehensive Literature Review and New Data on Prognosis in Breast Cancer Subtypes

Hunt

Kopacz

Vestal

2022

Cancers

View full text Add to dashboard Cite

show abstract

“…The colony formation assay was used to examine the cell colony formation ability of U87MG ATCC and U251 cells following USP18 expression knockdown. The colony formation assay was performed as previously described ( 32 ). Clusters of >50 cells were regarded as colonies.…”

Section: Methodsmentioning

confidence: 99%

Bulk and single cells transcriptomes with experimental validation identify USP18 as a novel glioma prognosis and proliferation indicator

Chen,

Li,

et al. 2024

Exp Ther Med

Self Cite

View full text Add to dashboard Cite

The mechanism by which ubiquitin-specific protease 18 (USP18) (enzyme commission: 3.4.19.12) inhibition in cancer promotes cell pyroptosis via the induction of interferon (IFN)-stimulated genes has been recently demonstrated. It is also known that USP18 influences the epithelial-mesenchymal transition of glioma cells. In the present study, the upregulation of USP18 in glioma was revealed through bulk transcriptome analysis, which was associated with poor prognosis in patients with glioma. Furthermore, USP18 levels affected the response to immunotherapy in patients with glioma. Single-cell transcriptome and enrichment analyses demonstrated that USP18 was associated with type 1 IFN responses in glioma T cells. To demonstrate the effect of USP18 expression levels on glioma cells, USP18 expression was knocked down in U251 and U87MG ATCC cell lines. A subsequent Cell Counting Kit-8 assay revealed that glioma cell viability was significantly decreased 4 days after USP18 knockdown. In addition, the knockdown of USP18 expression significantly inhibited the clonogenicity of U251 and U87MG ATCC cells. In conclusion, the present study demonstrated that knockdown of USP18 expression inhibited the proliferation of glioma cells, which may be mediated by the effect of USP18 on the IFN-I response.

show abstract

“…GBP2, a GTP (guanylate-binding protein) superfamily member, plays a significant role in carcinoma. It was reported that GBP2 inhibits mitochondrial fission and cell invasion in several types of tumors (Ren et al, 2022). However, the function of GBP2 in melanoma has not been revealed.…”

Section: Generation and Validation Of Icb Scorementioning

confidence: 98%

Identification of Crucial Gene Modules Related to the Efficiency of Anti-PD-1/PD-L1 Therapy and Comprehensive Analyses of a Novel Signature Based on These Modules

et al. 2022

View full text Add to dashboard Cite

Biomarker development for clinical checkpoint inhibition is still in its early stages. It is critical to determine the cause of the lack of a long-term response in patients after immune checkpoint blockade (ICB) treatment and to develop composite biomarkers or signatures to improve personalized approaches. Three modules that were significantly correlated with the immunotherapeutic response were identified. Stimulatory pathways of cellular immunity, extracellular matrix formation-related pathways, and ATP metabolism-related pathways were enriched. Two distinct transcriptional subtypes were determined. Tumor microenvironment (TME) characteristics were highly correlated with “hot” and “cold” tumors. The ICB score was significantly correlated with clinical characteristics including age, Breslow depth, Clerk level, AJCC stage, and T stage. Meanwhile, a low ICB score is characterized by increased activation of immunity, a higher level of immune infiltration, and immune molecule expression. The ICB score showed a robust ability to predict melanoma prognosis in the discovery, internal validation, and external validation cohorts. In addition, a low ICB score was linked to a higher CR/PR rate in the immunotherapeutic cohort. The ICB score could reflect the pre-existing immune features and the expression pattern of “Cold” versus “Hot” tumors in melanoma patients. Thus, it has the potential to serve as a reliable predictor of melanoma prognosis and response to ICB therapy.

show abstract

GBP2 facilitates the progression of glioma via regulation of KIF22/EGFR signaling

Cited by 17 publications

References 31 publications

Unraveling the Role of Guanylate-Binding Proteins (GBPs) in Breast Cancer: A Comprehensive Literature Review and New Data on Prognosis in Breast Cancer Subtypes

Unraveling the Role of Guanylate-Binding Proteins (GBPs) in Breast Cancer: A Comprehensive Literature Review and New Data on Prognosis in Breast Cancer Subtypes

Bulk and single cells transcriptomes with experimental validation identify USP18 as a novel glioma prognosis and proliferation indicator

Identification of Crucial Gene Modules Related to the Efficiency of Anti-PD-1/PD-L1 Therapy and Comprehensive Analyses of a Novel Signature Based on These Modules

Contact Info

Product

Resources

About